NDA 018735 · Bracco
Isovue-250
Iopamidol · Injection · Radiographic Contrast Agent
NovelLast checked: Nov 20, 2026Latest source record: Jan 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Dec 31, 1985
Approved uses
12
Original approval plus efficacy supplements
Registered trials
37
2 Phase 3, 1 recruiting
FAERS reports
2,986
2,177 serious, 263 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration of ISOVUE, even if inadvertent, can cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema [see Warnings and Precautions ( 5.1 )]. ISOVUE is for intra-arterial, intravenous, or oral use only [see Dosage and Administration ( 2.2 , 2.3 , 2.4 , 2.5 )] . WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration of ISOVUE, even if inadvertent, can cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ISOVUE is for intra-arterial, intravenous, or oral use only. ( 5.1 )
What it is approved for
From the label in effect Mar 10, 2026.
ISOVUE is a radiographic contrast agent indicated for: Intra-arterial Procedures † ( 1.1 ) Cerebral arteriography in adults Peripheral arteriography in adults Selective visceral arteriography and aortography in adults Coronary arteriography and cardiac ventriculography in adults Angiocardiography in pediatric patients Intravenous Procedures † ( 1.2 ) Excretory urography in adults and pediatric patients Computed tomography (CT) of head and body in adults and pediatric patients Peripheral venography in adults Oral Procedures † ( 1.3 ) CT of the abdomen and pelvis to delineate the gastrointestinal tract in adults and pediatric patients † Specific concentrations are recommended for each type of imaging procedure. ( 2.2 , 2.3 , 2.4 , 2.5 ) 1.1 Intra-arterial Procedures † ISOVUE is indicated for: Cerebral arteriography in adults Peripheral arteriography in adults Selective visceral arteriography and aortography in adults Coronary arteriography and cardiac ventriculography in adults Angiocardiography in pediatric patients 1.2 Intravenous Procedures † ISOVUE is indicated for: Excretory urography in adults and pediatric patients Computerized tomography (CT) of the head and body in adults and pediatric patients Peripheral venography in adults 1.3 Oral Procedures † ISOVUE is indicated for: CT of the abdomen and pelvis to delineate the gastrointestinal tract in adults and pediatric patients † Specific concentrations of ISOVUE are recommended for each type of imaging procedure [see Dosage and Administration ( 2.2 , 2.3 , 2.4 , 2.5 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 2025 Supplement 75 · Efficacy LetterLabel
- Mar 4, 1996 Supplement 33 · Efficacy
- May 15, 1995 Supplement 36 · Efficacy
- Jul 6, 1992 Supplement 25 · Efficacy
- Sep 21, 1990 Supplement 23 · Efficacy
- May 30, 1990 Supplement 21 · Efficacy
- Jan 18, 1990 Supplement 10 · Efficacy
- Oct 4, 1989 Supplement 12 · Efficacy
- Jul 7, 1987 Supplement 8 · Efficacy
- Oct 21, 1986 Supplement 3 · Efficacy
- Sep 10, 1986 Supplement 2 · Efficacy
- Dec 31, 1985 Original approval · Type 1 - New Molecular Entity
7 products under this application
- ISOVUE-250 · IOPAMIDOL 51% · INJECTABLE, INJECTION · Prescription · TE AP
- ISOVUE-128 · IOPAMIDOL 26% · INJECTABLE, INJECTION · Discontinued
- ISOVUE-370 · IOPAMIDOL 76% · INJECTABLE, INJECTION · Prescription · TE AP
- ISOVUE-M 200 · IOPAMIDOL 41% · INJECTABLE, INJECTION · Prescription · TE AP1
- ISOVUE-200 · IOPAMIDOL 41% · INJECTABLE, INJECTION · Prescription · TE AP2
- ISOVUE-M 300 · IOPAMIDOL 61% · INJECTABLE, INJECTION · Prescription · TE AP
- ISOVUE-300 · IOPAMIDOL 61% · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Iopamidol" as an intervention, any sponsor and status, largest first.
- Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed TomographyPivotal-lookingTerminated
GE HealthcareIndustry
NCT00209417 · 656 participants · Start Jun 2005 · Primary completion May 2011
Drug: Iodixanol 320-Arm 1; Iopamidol 300-Arm 2 · For: Renal Insufficiency; Diabetes Mellitus
Sites: Princeton, New Jersey; Amersham, United Kingdom
- Effects of Contrast Media Temperature on Image Quality and Clinical Adverse Events in Coronary CTAPivotal-lookingStatus unknown
Chongqing Emergency Medical CenterAcademic, hospital or other
NCT05489055 · 500 participants (planned) · Start Feb 1, 2022 · Primary completion Jan 1, 2023
Drug: Iopamidol · For: Contrast Media Adverse Reaction
Sites: Chongqing, China
- Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary AngiographyPivotal-lookingCompleted
GE HealthcareIndustry
NCT00209430 · 408 participants · Start Aug 2005
Drug: Iodixanol 320 mgI/mL · For: Coronary Artery Disease; Renal Impairment
Sites: Solna, Sweden
- A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac AngiographyPivotal-lookingCompleted
Bracco Diagnostics, IncIndustry
NCT00289029 · 400 participants · Start Jul 2005
Drug: Iopamidol 370 mgI/mL · For: CIN
Sites: Princeton, New Jersey
- Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)Pivotal-lookingCompleted
Bracco Diagnostics, IncIndustry
NCT00289614 · 350 participants (planned) · Start Jan 2006
Drug: Iopamidol 370 mgI/dL · For: Kidney Diseases
Sites: Princeton, New Jersey
- Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/PelvisPivotal-lookingCompleted
GE HealthcareIndustry
NCT01376089 · 304 participants · Start May 2011 · Primary completion Oct 2011
Drug: Iodixanol; Iopamidol · For: Patient Comfort and Safety
Sites: Princeton, New Jersey
- Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary ProcedurePivotal-lookingCompleted
GE HealthcareIndustry
NCT01252810 · 284 participants · Start Nov 2010 · Primary completion Dec 2012
Drug: GE-145 · For: Chronic Renal Insufficiency; Diabete Mellitus; Congestive Heart Failure
Sites: Princeton, New Jersey
- Optimization of Contrast Agent Dose in CT With Lean Body WeightPivotal-lookingCompleted
IRCCS Policlinico S. DonatoAcademic, hospital or other
NCT03384979 · 274 participants · Start Dec 18, 2017 · Primary completion Feb 25, 2019
Drug: Iopamidol · For: Contrast Agent With Lean Body Weight
Sites: San Donato Milanese, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea192
- urticaria191
- anaphylactic reaction186
- pruritus174
- nausea165
- contrast media reaction145
- no adverse event145
- vomiting124
- acute kidney injury116
- hypersensitivity110
- off label use98
- dizziness89
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 36 |
| 2006 | 7 |
| 2007 | 20 |
| 2008 | 25 |
| 2009 | 24 |
| 2010 | 59 |
| 2011 | 83 |
| 2012 | 78 |
| 2013 | 136 |
| 2014 | 155 |
| 2015 | 156 |
| 2016 | 164 |
| 2017 | 208 |
| 2018 | 207 |
| 2019 | 282 |
| 2020 | 172 |
| 2021 | 193 |
| 2022 | 186 |
| 2023 | 140 |
| 2024 | 169 |
| 2025 | 185 |
| 2026 | 269 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bowel cleansing before CT colonography: comparison between two minimal-preparation regimens.
Iafrate F, Iannitti M, Ciolina M, et al. · Eur Radiol 2015 · Comparative Study, Randomized Controlled Trial
- Double-blind study of a new nonionic contrast agent for digital subtraction arteriography.
Weiss JP, McLean GK, Modic MT, et al. · Invest Radiol 1994 · Clinical Trial, Comparative Study
- Iopamidol in cardioangiography: a retrospective, multicentre study. Part II. Paediatric patients.
Ballerini L, Barbaresi F, Binaghi G, et al. · Int J Card Imaging 1992 · Clinical Trial, Multicenter Study
- [Myelography and headache].
Hammer B · Wien Med Wochenschr 1985 · Clinical Trial, Controlled Clinical Trial
- Iopamidol as contrast medium in endoscopic retrograde pancreatography: a prospective randomised comparison with diatrizoate.
O'Connor HJ, Ellis WR, Manning AP, et al. · Endoscopy 1988 · Clinical Trial, Comparative Study
- Cost-effectiveness of iso- versus low-osmolality contrast media in outpatients with high risk of contrast medium-induced nephropathy.
Chicaíza-Becerra LA, García-Molina M, Gamboa Ó · Biomedica 2012 · Comparative Study, Research Support, Non-U.S. Gov't
Sponsor: Bracco · Also marketed as Isovue-128, Isovue-370, Isovue-M 200, Isovue-200, Isovue-M 300
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.